TABLE 1.
Summary of clinical characteristics of ESCA patients in three cohorts.
| Characteristic | Patients in entire TCGA set (n = 159), n (%) | Patients in subgroup 1 (n = 79), n (%) | Patients in subgroup 2 (n = 80), n (%) |
|---|---|---|---|
| Age (years) | |||
| ≤60 | 81 (50.94%) | 44 (55.70%) | 37 (46.25%) |
| >60 | 78 (49.06%) | 35 (44.30%) | 43 (53.75%) |
| Gender | |||
| Female | 23 (14.47%) | 13 (16.46%) | 10 (12.50%) |
| Male | 136 (85.53%) | 66 (83.54%) | 70 (87.5%) |
| Histological type | |||
| Esophagus adenocarcinoma, NOS | 79 (49.69%) | 36 (45.57%) | 43 (53.75%) |
| Esophagus squamous cell carcinoma | 80 (50.31%) | 43 (54.43%) | 37 (46.25%) |
| Vital status | |||
| Alive | 96 (60.38%) | 47 (59.49%) | 49 (61.25%) |
| Dead | 63 (39.62%) | 32 (40.51%) | 31 (38.75%) |
| Pathologic stage | |||
| Stage I-II | 87 (54.72%) | 46 (58.23%) | 41 (51.25%) |
| Stage III-IV | 68 (42.77%) | 32 (40.51%) | 36 (45.00%) |
| NA | 4 (2.51%) | 1 (1.26%) | 3 (3.75%) |
| Race | |||
| Asian | 38 (23.90%) | 22 (27.85%) | 16 (20.00%) |
| Black or african american | 5 (3.14%) | 2 (2.53%) | 3 (3.75%) |
| White | 98 (61.64%) | 50 (63.29%) | 48 (60.00%) |
| NA | 18 (11.32%) | 5 (6.33%) | 13 (16.25%) |
| N Classification | |||
| N0-N1 | 133 (83.65%) | 65 (82.28%) | 68 (85.00%) |
| N2-N3 | 14 (8.80%) | 7 (8.86%) | 7 (8.75%) |
| NA | 12 (7.55%) | 7 (8.86%) | 5 (6.25%) |
| T classification | |||
| T1 | 25 (15.72%) | 14 (17.72%) | 11 (13.75%) |
| T2-T4 | 132 (83.02%) | 63 (79.75%) | 69 (86.25%) |
| NA | 2 (1.26%) | 2 (2.53%) | 0 (0.00%) |
| M classification | |||
| M0 | 126 (79.25%) | 59 (74.68%) | 67 (83.75%) |
| M1 | 15 (9.43%) | 7 (8.86%) | 8 (10.00%) |
| NA | 18 (11.32%) | 13 (16.46%) | 5 (6.25%) |
| Neoplasm cancer status | |||
| Tumor free | 91 (57.23%) | 49 (62.03%) | 42 (52.50%) |
| With tumor | 58 (36.48%) | 26 (32.91%) | 32 (40.00%) |
| NA | 10 (6.29%) | 4 (5.06%) | 6 (7.5%) |
| Tumor central location | |||
| Distal | 111 (69.81%) | 54 (68.35%) | 57 (71.25%) |
| Mid | 41 (25.79%) | 22 (27.85%) | 19 (23.75%) |
| Proximal | 6 (3.77%) | 3 (3.80%) | 3 (3.75%) |
| NA | 1 (0.63%) | 0 (0.00%) | 1 (1.25%) |
| Neoplasm histologic grade | |||
| G1 | 16 (10.06%) | 6 (7.6%) | 10 (12.5%) |
| G2 | 65 (40.88%) | 33 (41.77%) | 32 (40.00%) |
| G3 | 43 (27.05%) | 23 (29.11%) | 20 (25.00%) |
| NA | 35 (22.01%) | 17 (21.52%) | 18 (22.50%) |
| Residual tumor | |||
| R0 | 119 (74.84%) | 60 (75.95%) | 59 (73.75%) |
| R1+R2 | 13 (8.18%) | 3 (3.80%) | 10 (12.50%) |
| NA | 27 (16.98%) | 16 (20.25%) | 11 (13.75%) |
| Lymph node metastasis | |||
| NO | 83 (52.20%) | 34 (43.04%) | 49 (61.25%) |
| Yes | 43 (27.04%) | 27 (34.18%) | 16 (20.00%) |
| NA | 33 (20.76%) | 18 (22.78%) | 15 (18.75%) |
Abbreviations: ESCA, esophageal cancer; NA, not available.